Welcome to...The UCLA Endocrine Surgical Unit
 

Schedule an Appointment
Endocrine Home
About Us
Our Expert Team
Our Services
First Visit for Patients
Patient Education
Scar Gallery
For Referring Physicians
Distance Surgery Program
International Patients
Insurance Questions
Map-Directions-Parking
Contact Us
Patient Experiences
Endocrine Resources
Site Map

UCLA Health System


Schedule an Appointment


Parathyroid News Feeds

Worldwide News: View Endocrine News | View Parathyroid News


Fri, 18 Jul 2014 16:30:34 GMT
• Amgen parathyroid drug for dialysis patients reaches endpoints in phase 3 study - NephrologyNews.com

Amgen parathyroid drug for dialysis patients reaches endpoints in phase 3 study
NephrologyNews.com
Amgen announced that more than 75% of hemodialysis patients who received the experimental drug AMG 416 (formerly known as velcalcetide) as part of a phase 3 study experienced a drop in their parathyroid hormone levels of more than 30%, compared ...

and more »

Fri, 18 Jul 2014 16:02:44 GMT
• PTH Drug Passes Test in Dialysis Patients - MedPage Today

PTH Drug Passes Test in Dialysis Patients
MedPage Today
In a press release on top-line results of a 515-patient phase III trial, the company said its drug AMG 416 (formerly known as velcalcetide) reduced parathyroid hormone (PTH) levels by at least 30% from baseline in 75.3% of patients compared with only 9.6% of ...

and more »

Fri, 18 Jul 2014 14:59:38 GMT
• Positive Phase 3 Results in Secondary Hyperparathyroidism with AMG 416 - Monthly Prescribing Reference

Positive Phase 3 Results in Secondary Hyperparathyroidism with AMG 416
Monthly Prescribing Reference
The study met its primary endpoint, which was defined as the proportion of patients with >30% reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. In the ...

and more »

Fri, 18 Jul 2014 11:58:47 GMT
• Amgen's Sensipar follow-up clears phase III trial - PMLiVE

Amgen's Sensipar follow-up clears phase III trial
PMLiVE
AMG 416 was significantly more effective than placebo in improving parathyroid hormone (PTH) levels by 30 per cent or more in the six-month study, achieving that objective in 75 per cent of patients, compared to less than 10 per cent of the placebo arm.

and more »

Fri, 18 Jul 2014 11:18:54 GMT
• Amgen's Thyroid Drug Shows Promise For Kidney Patients - Bidness Etc

Bidness Etc

Amgen's Thyroid Drug Shows Promise For Kidney Patients
Bidness Etc
In the condition, excessive parathyroid hormone (PTH) is produced to compensate for the declining kidney function. This leads to abnormal calcium and phosphorous levels in the body, which lead to significant clinical consequences. The drug will treat thyroid ...

and more »


Worldwide "Parathyroid" News Courtesy of Google News